VA
WHWK

VR Adviser’s Whitehawk Therapeutics WHWK Stock Holding History

VR Adviser’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,173,518
Closed -$14.5M – 35
2022
Q2 		$14.5M Sell
1,173,518
-355,884
-23% -$5.29M 2.85% 12
2022
Q1 		$26M Hold
1,529,402
– – 4.2% 10
2021
Q4 		$36.9M Hold
1,529,402
– – 5.05% 6
2021
Q3 		$44.9M Buy
+1,529,402
New +$46.6M 5.77% 4

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser's WHWK Position: Q3 2022 in Review

VR Adviser sold out of Whitehawk Therapeutics (WHWK) in Q3 2022, closing a stake of 1,173,518 shares — an estimated $14.5M sold.

VR Adviser first reported a position in WHWK in Q3 2021 and held it in 4 quarters. The position peaked at $44.9M in Q3 2021. 68 funds tracked by Wall St. Rank hold WHWK as of Q3 2022.

  • VR Adviser reported no remaining Whitehawk Therapeutics position as of Q3 2022 after selling out during the quarter.
  • VR Adviser sold 1,173,518 Whitehawk Therapeutics shares in Q3 2022, an estimated $14.5M.
  • VR Adviser first reported a position in Whitehawk Therapeutics in Q3 2021 and held it in 4 quarters.
  • VR Adviser's Whitehawk Therapeutics position peaked at $44.9M in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2022.

Based on VR Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.